School of Medicine, The University of Adelaide, Adelaide, SA, Australia.
Department of Gastroenterology & Hepatology, Royal Adelaide Hospital, Adelaide, SA, Australia.
Neurogastroenterol Motil. 2018 Jan;30(1). doi: 10.1111/nmo.13243. Epub 2017 Nov 2.
Recent advances in the development of diagnostic criteria and effective management options for functional gastrointestinal disorders (FGIDs) have not yet been integrated into clinical practice. There is a clear need for the development and validation of a simple clinical pathway for the diagnosis and management of FGIDs which can be used in primary care.
In this controlled pilot study, we designed and evaluated a non-specialist-dependent, algorithm-based approach for the diagnosis and management of FGIDs (ADAM-FGID). Patients referred to 1 tertiary referral center with clinically suspected functional gastrointestinal disorders were allocated to waitlist control or algorithm group. The algorithm group was screened for organic disease, and those without clinical alarms received a written FGID diagnosis and management options. All participants were followed up for 1 year.
The ADAM-FGID was found to be feasible and acceptable to both patients and primary healthcare providers. The diagnostic component identified that 39% of referrals required more urgent gastroenterological review than original triage category, with organic disease subsequently diagnosed in 31% of these. The majority of patients (82%) diagnosed with a FGID did not receive a relevant alternative diagnosis during follow-up. Patient buy-in to the model was good, with all reading the diagnostic/management letter, 80% entering management, and 61% reporting symptom improvement at 6 weeks. Moreover, 68% of patients and all referring doctors found the approach to be at least moderately acceptable. Patients reported being reassured by the approach and found the management options useful. Primary healthcare providers acknowledged the potential of this approach to reduce waiting times for endoscopic procedures and to provide reassurance to both patients and themselves.
CONCLUSIONS & INFERENCES: This pilot study provides preliminary evidence to support a clinical pathway for the diagnosis and management of FGIDs which does not depend upon specialist review. Further rigorous testing within primary care is needed to conclusively establish safety and efficacy. However, this approach is safer than current management and has potential to build capacity by reducing specialist burden and expediting effective care.
尽管在功能性胃肠病(FGIDs)的诊断标准和有效管理选择方面取得了新进展,但这些进展尚未在临床实践中得到整合。显然需要开发和验证一种简单的临床路径,用于 FGIDs 的诊断和管理,以便在初级保健中使用。
在这项对照性试点研究中,我们设计并评估了一种非专科医生依赖的、基于算法的 FGIDs 诊断和管理方法(ADAM-FGID)。将转诊至一家三级转诊中心的疑似 FGIDs 患者分配至等待名单对照组或算法组。对算法组进行了器质性疾病筛查,对于没有临床警报的患者,会收到书面的 FGID 诊断和管理选择。所有参与者均随访 1 年。
ADAM-FGID 被认为是可行且可接受的,既适用于患者,也适用于初级保健提供者。诊断部分发现,39%的转诊需要比最初分诊类别更紧急的胃肠病学审查,其中 31%的患者随后被诊断为器质性疾病。在随访期间,大多数(82%)被诊断为 FGID 的患者没有得到相关的替代诊断。患者对该模型的接受度良好,所有患者均阅读了诊断/管理信件,80%的患者进入了管理流程,61%的患者在 6 周时报告症状改善。此外,68%的患者和所有转诊医生认为该方法至少在一定程度上是可接受的。患者表示对该方法感到放心,并认为管理方案很有用。初级保健提供者承认这种方法有可能减少内镜检查的等待时间,并为患者和自己提供保证。
这项试点研究提供了初步证据,支持一种不依赖专科医生评估的 FGIDs 诊断和管理的临床路径。需要在初级保健中进一步进行严格测试,以确定其安全性和有效性。然而,与当前的管理方法相比,该方法更安全,并且通过减轻专科医生的负担和加快有效的治疗,有可能增加治疗容量。